Alkem Laboratories

“So next 12 months will not breakeven, just to be very clear. For U.S., we will not breakeven.”

“I think it will be high single digit to mid.”

“And second part, at some point of time, it will require capex to happen over there as we ramp up because without it, we'll not really get economies of scale, just like any API/CDMO or biotech business. And that will not be this year.”

“So we have reasonable capacity. We are not very big. We have small capacity, but the technology is a little different.”

“I think we've got a decent pipeline. A CDMO has a sales cycle very different from what we traditionally do as branded pharma. So I think we'll have to be patient over there.”

“And also CDMO is a lumpy business, as you know. So when it rains, it pours kind of things. We don't -- whenever it comes, it will come big, we feel.”

“India sales were INR2,497 crores and year-on-year growth was 10.3%.”

“International sales was INR1,222 crores with year-on-year growth of 16%. EBITDA margin was 20.5%.”

“Trade Generics growth was flattish to a very mild growth and Trade Generics now contribute reasonably to our domestic formulation. So that dragged it downside.”

“So there are many, many players even in Europe, just like U.S. So it's not going to be a very meaningful ramp-up for any one of us for some time.”

“So we have already launched 7 products, as you said, and we do around INR150 crores of annual sales.”

“Chronic segment reported a growth of 17.9% versus the IPM, which grew by 15.4%, 250 basis point outperformance.”

“I think semaglutide has gone off patent and -- so those kind of things are driving Chronic, I think, by and large. And so we think it's quite sustainable whatever we are doing at least.”

“Acute segment reported a growth of 12.3% versus the IPM, which grew by 10.1%, which is a 220 basis point outperformance.”

“We have outperformed IPM in 7 key focus therapies.”

“It has got very intensive, the competition. 4, 5 years back, you will remember that not many companies wanted to play in this segment, but now a lot of big guys have entered.”

“The growth was 3.7% year-on-year. R&D expenses was 4% of our total revenue. Profit before tax was more or less flattish, technically 1.8% of growth.”

“So in terms of employee cost, yes, the growth is more than 16% in the quarter. There are 2, 3 reasons. One is definitely the annual increment. The second is we have added around 1,200 MRs in the last few quarters.”

“if we exclude the diligence cost and all of Occlutech, there was an EBITDA loss of around INR5 crores to INR7 crores because we are also investing into this business.”

“You can annualize that. Opex will remain the same. We have to get business, and that's how we can break even and eventually make money.”

“So overall, the mix was better for us because of lower Trade Generic business and also support from the currency side helped us.”

“During the quarter, for the U.S. market, the company received 5 ANDAs approval. One of them was a tentative approval.”

“MedTech, yes, we have completed the acquisition of Occlutech, but that was in mid of July. So our quarter 1 numbers were not impacted because of Occlutech.”

“We could be like 3 months away.”

“So we are not looking to acquire anything in orthopedics or MedTech right now.”

“Yes, we would be.”

“So we told you last time, we are looking out. So thoughts are the same. And hopefully, next time when we have the quarterly meeting, he'll be there with you.”

“While this represents an important regulatory development, approved product supplies from the facility continue to the U.S. market without any interruption.”

“So we did not get the approval on the goal date. So that is pushed off by at least a few months.”

“I think 45% of our U.S. revenue comes from this facility.”

“So I think we knew that it's going to be expensive and business would pick up, but it's taking more than, let's say, a couple of quarters to reach what numbers we were targeting.”

“Recently, our Daman facility has received an OAI status. We have already initiated comprehensive corrective and preventive actions and remain fully engaged with the regulator to address the observations.”

“The key highlights are that our revenue from operation was INR3,740 crores with a year-on-year growth of close to 11%.”

“In terms of other expenses, yes, there were expenses on account of Enzene CDMO business, plus the conversion rate for dollar has increased, which has also benefited us in terms of top line, but the impact is also on other expenses where all our subsidiaries, foreign subsidiaries expenses got converted at a higher rate. It's almost 10% higher than the last year rate.”

“No, nothing. Everything is the same like before. Nothing changed from last quarter.”